Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea

Inclusion Criteria:

• Subject with facial vascular rosacea with flushing, permanent redness,telangiectasias and at least 3 papules and/or pustules (this last criterion for atleast 10 subjects per group)

• Subject starting local treatment for rosacea (Ivermectin or metronidazole)

• Female aged 18 to 65 years old,

• Subject of all types of skin

• Subject of I to IV phototype.

• Subject accepting not to use any type of facial skin care other than the studyproduct

• Subject willing to keep their usual habits and products (hygiene products,sunscreen, and make-up, if applicable)

• Subject willing to avoid sun exposure during the study period

• Subject willing to actively participate in the study and to come to the scheduledvisits

• Subject that has signed informed consent

Exclusion Criteria:

• Pregnant or breastfeeding woman

• Subject showing cutaneous marks on the experimental areas, which could interferewith the assessment of skin reactions (pigmentation troubles, scar elements,over-developed pilosity, ephelides and naevi in too great quantity, sunburn)

• Subject with documented allergy or reactivity to products of the same category thanthe tested one

• Subject with documented allergies to study product components

• Subject with history of malignant melanomas (Dubreuilh melanosis...)

• Subject with unbalanced hormonal treatment

• Subject with forecast of initiation of a hormonal treatment or change of the usualhormonal treatment during the study period

• Subject with forecast of sun or UVA exposure (UV lamps) during the study period

• Subject not willing to use sun protective clothes orhat if exposed to the sun

• Subject not willing to respect the methods of use of the treatment, study productand sunscreen

• Subject with anti-ageing or aesthetic treatment during the last 6 months: botox orbotox like products, peelings, plastic surgery, hyaluronic acid treatment, PlasmaRich Platelets treatment, or any other specific treatments prone to change the skinaspect

• Subject with antibiotic, anti-allergic, anti-inflammatory treatment or treatmentwith patent medicines containing Vitamin A acid or its derivatives within 4 weeksand during the study (if therapeutic requirement: exclusion foreseen),

• Subject with systemic disorder: cardiovascular, pulmonary, digestive, neurologic,psychiatric, genital, urinary, haematological, endocrine

• Subject presenting chronic diseases with impact on skin

• Subject who has undergone a bilateral mastectomy with lymph node removal, aunilateral mastectomy with lymph node removal within the last year, or a bilateralaxillary lymph node removal,

• Subject with a history of immune deficiency or auto-immune disease, treated formalignancy within 6 months prior to enrolment or who are currently under treatmentfor asthma or diabetes, forecast of vaccination during the test period or lastvaccination within 3 weeks before the study.

• Subject receiving local treatment for rosacea (cyclins, isotretinoin) or who hasundergone local active treatment for rosacea (erythromycin, metronidazole, benzoylperoxide, ivermectin) within 4 weeks before inclusion in the study

• Subject who has had oral treatment with metronidazole or cyclins within 4 weeksbefore inclusion in the study

• Subject who has had topical or oral anti-inflammatory and/or antiallergy treatment (corticosteroid, antihistamine, anti-inflammatory drugs, immunosuppressives) within 4 weeks before inclusion in the study

• Subject who has had oral treatment with retinoids within 2 months before inclusionin the study

• Subject currently receiving electrocoagulation or laser treatment for telangiectasia